Biomarker ID | 28 |
PMID | 11757030 |
Year | 2001 |
Biomarker | Insulin |
Biomarker Basis | Concentration Based (μIU/m) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in High Risk Group |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Vitamin B12 metabolism,Signaling events mediated by PTP1B,Selenium pathway,Amyloids,Folate metabolism |
Experiment | High vs (Medium and Low) Risk |
Type of Biomarker | Prognostic |
Cohort | 112 patients were chosen for study and divided into 3 groups. Low Risk: 52 patients, Medium Risk: 16 patients, High Risk: 44 patients. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p= 0.05 |
Method Used | Chemoluminescent assay |
Clinical | No |
Remarks | Low Risk: Serum PSA ≤ 10, stage ≤ T2a, or Gleason grade ≤ 6. Medium Risk: Serum PSA 10-15, Gleason =7 or stage ≤ T2b. High Risk: Gleason > 7, tumor in seminal vesicle biopsy, serum PSA > 15 or stage T2c or T3 |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | INS |